Literature DB >> 10640762

IL-13 is a susceptibility factor for Leishmania major infection.

D J Matthews1, C L Emson, G J McKenzie, H E Jolin, J M Blackwell, A N McKenzie.   

Abstract

Leishmania major infection is useful as an experimental model to define factors responsible for the development and maintenance of Th cell immune responses. Studies using inbred mouse strains have identified that the Th1 response characteristic of C57BL/6 mice results in healing, whereas BALB/c mice fail to control the infection due to the generation of an inappropriate Th2 response. We now demonstrate that IL-13 is a key factor in determining susceptibility to L. major infection. Overexpression of IL-13 in transgenic mice makes the normally resistant C57BL/6 mouse strain susceptible to L. major infection even in the absence of IL-4 expression. This susceptibility correlates with a suppression of IL-12 and IFN-gamma expression. Furthermore, using BALB/c mice deficient in the expression of IL-4, IL-13, or both IL-13 and IL-4, we demonstrate that IL-13-deficient mice are resistant to infection and that there is an additive effect of deleting both IL-4 and IL-13.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640762     DOI: 10.4049/jimmunol.164.3.1458

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  46 in total

Review 1.  Concepts of immunostimulation to increase antiparasitic drug action.

Authors:  K Noel Masihi
Journal:  Parasitol Res       Date:  2003-01-08       Impact factor: 2.289

2.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

Review 3.  Sex hormones and modulation of immunity against leishmaniasis.

Authors:  Heidi Snider; Claudio Lezama-Davila; James Alexander; Abhay R Satoskar
Journal:  Neuroimmunomodulation       Date:  2009-02-11       Impact factor: 2.492

4.  Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.

Authors:  Alexander B Mullen; Catherine E Lawrence; Emma McFarlane; Xiao-Quing Wei; Katharine C Carter
Journal:  Immunology       Date:  2006-07-26       Impact factor: 7.397

5.  Pretreatment with recombinant Flt3 ligand partially protects against progressive cutaneous leishmaniasis in susceptible BALB/c mice.

Authors:  I B Kremer; M P Gould; K D Cooper; F P Heinzel
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

6.  Immunological determinants of clinical outcome in Peruvian patients with tegumentary leishmaniasis treated with pentavalent antimonials.

Authors:  Anne Maurer-Cecchini; Saskia Decuypere; François Chappuis; Coralie Alexandrenne; Simonne De Doncker; Marleen Boelaert; Jean-Claude Dujardin; Louis Loutan; Jean-Michel Dayer; Gianfranco Tulliano; Jorge Arevalo; Alexandro Llanos-Cuentas; Carlo Chizzolini
Journal:  Infect Immun       Date:  2009-02-23       Impact factor: 3.441

Review 7.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

8.  Mice deficient in interleukin-4 (IL-4) or IL-4 receptor alpha have higher resistance to sporozoite infection with Plasmodium berghei (ANKA) than do naive wild-type mice.

Authors:  Michael Saeftel; Andreas Krueger; Sandra Arriens; Volker Heussler; Paul Racz; Bernhard Fleischer; Frank Brombacher; Achim Hoerauf
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

9.  Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.

Authors:  R G Titus; G K DeKrey; R V Morris; M B Soares
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

10.  Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major.

Authors:  Willy K Tonui; J Santiago Mejia; Lisa Hochberg; M Lamine Mbow; Jeffrey R Ryan; Adeline S T Chan; Samuel K Martin; Richard G Titus
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.